Infliximab Weakens COVID Antibody Response for Patients With IBD Infliximab Weakens COVID Antibody Response for Patients With IBD

Although anti-tumor necrosis factor (anti-TNF) drugs are routinely used for patients with IBD, the impact of their immune-suppressing properties on protective immunity to COVID-19 is unknown.Medscape Medical News
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Gastroenterology News Source Type: news